Published in J Am Coll Cardiol on November 05, 2003
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Truncations of titin causing dilated cardiomyopathy. N Engl J Med (2012) 6.07
Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med (2008) 2.12
Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet Med (2010) 1.90
Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA (2009) 1.75
Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail (2009) 1.74
Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor. Circ Res (2012) 1.69
Cardiomyopathy: an overview. Am Fam Physician (2009) 1.68
A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy. Eur Heart J (2012) 1.64
Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson (2012) 1.51
One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response. Clin Res Cardiol (2007) 1.35
Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Clin Res Cardiol (2007) 1.32
The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2012) 1.32
Computational modeling of growth: systemic and pulmonary hypertension in the heart. Biomech Model Mechanobiol (2010) 1.29
Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med Genet (2013) 1.27
Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart (2005) 1.24
Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart (2005) 1.24
Familial screening and genetic counselling in hypertrophic cardiomyopathy: the Rotterdam experience. Neth Heart J (2007) 1.23
Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction. J Cardiovasc Magn Reson (2012) 1.18
Management of hypertrophic cardiomyopathy. BMJ (2006) 1.18
Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation (2010) 1.18
Sudden cardiac death in young athletes; a literature review and special considerations in Asia. Asian J Sports Med (2011) 1.18
Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. Can J Cardiol (2008) 1.15
Genetics of hypertrophic cardiomyopathy. Curr Opin Cardiol (2010) 1.14
Genetics of inherited cardiomyopathy. Eur Heart J (2011) 1.11
Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nat Rev Cardiol (2016) 1.11
Enhanced active cross-bridges during diastole: molecular pathogenesis of tropomyosin's HCM mutations. Biophys J (2011) 1.08
Narrative review: harnessing molecular genetics for the diagnosis and management of hypertrophic cardiomyopathy. Ann Intern Med (2010) 1.07
Some cardiomyopathy-causing troponin I mutations stabilize a functional intermediate actin state. Biophys J (2009) 1.00
Hypertrophic cardiomyopathy in 2012. Circulation (2012) 0.98
Magnetic resonance imaging in the evaluation of non-ischemic cardiomyopathies: current applications and future perspectives. Heart Fail Rev (2006) 0.97
Optimization of ultrasound parameters of myocardial cavitation microlesions for therapeutic application. Ultrasound Med Biol (2014) 0.97
Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience. Clin Res Cardiol (2007) 0.96
Impaired contractile function due to decreased cardiac myosin binding protein C content in the sarcomere. Am J Physiol Heart Circ Physiol (2013) 0.96
Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment. Cardiovasc Ultrasound (2010) 0.96
Hypertrophic cardiomyopathy. Heart Fail Clin (2010) 0.95
Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart (2007) 0.95
Clinical utility of genetic tests for inherited hypertrophic and dilated cardiomyopathies. Cardiovasc Ultrasound (2008) 0.93
Contemporary management of atrial fibrillation: update on anticoagulation and invasive management strategies. Mayo Clin Proc (2009) 0.93
The pre-participation examination for leisure time physical activity: general medical and cardiological issues. Dtsch Arztebl Int (2010) 0.93
Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands. Neth Heart J (2010) 0.92
The decision-making process of genetically at-risk couples considering preimplantation genetic diagnosis: initial findings from a grounded theory study. Soc Sci Med (2012) 0.92
National Athletic Trainers' Association position statement: Preparticipation physical examinations and disqualifying conditions. J Athl Train (2014) 0.91
The missing spade: apical hypertrophic cardiomyopathy investigation. Int J Cardiovasc Imaging (2008) 0.90
Focal energy deprivation underlies arrhythmia susceptibility in mice with calcium-sensitized myofilaments. Circ Res (2013) 0.89
Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy. J Cardiovasc Comput Tomogr (2013) 0.89
Several cardiomyopathy causing mutations on tropomyosin either destabilize the active state of actomyosin or alter the binding properties of tropomyosin. Biochem Biophys Res Commun (2011) 0.89
Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German Cardiac Society. Z Kardiol (2005) 0.88
Use of Theranostic Strategies in Myocardial Cavitation-Enabled Therapy. Ultrasound Med Biol (2015) 0.87
Subclinical echocardiographic abnormalities in phenotype-negative carriers of myosin-binding protein C3 gene mutation for hypertrophic cardiomyopathy. Am Heart J (2011) 0.86
Myocardial scarring on cardiovascular magnetic resonance in asymptomatic or minimally symptomatic patients with "pure" apical hypertrophic cardiomyopathy. J Cardiovasc Magn Reson (2012) 0.86
Hypertrophic cardiomyopathy in childhood. Heart Fail Clin (2010) 0.86
Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction. Heart Vessels (2015) 0.85
Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies. World J Cardiol (2014) 0.85
Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all. Expert Rev Mol Diagn (2010) 0.85
Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy. J Transl Med (2015) 0.85
Comparison and effectiveness of regadenoson versus dipyridamole on stress electrocardiographic changes during positron emission tomography evaluation of patients with hypertrophic cardiomyopathy. Am J Cardiol (2012) 0.84
The emerging role of cardiovascular magnetic resonance in refining the diagnosis of hypertrophic cardiomyopathy. Nat Clin Pract Cardiovasc Med (2009) 0.84
Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: Dutch cardiologists and the care of mutation carriers. Neth Heart J (2009) 0.84
Cardiac computed tomographic imaging to evaluate myocardial scarring/fibrosis in patients with hypertrophic cardiomyopathy: a comparison with cardiac magnetic resonance imaging. Int J Cardiovasc Imaging (2012) 0.84
Cardiomyopathies: focus on cardiovascular magnetic resonance. Br J Radiol (2011) 0.83
Apical myocardial injury caused by collateralisation of a septal artery during ethanol septal ablation. Heart (2005) 0.83
Hypertrophic cardiomyopathy: a review. Clin Med Insights Cardiol (2015) 0.83
A study of tropomyosin's role in cardiac function and disease using thin-filament reconstituted myocardium. J Muscle Res Cell Motil (2013) 0.83
Approach to Hypertrophic Cardiomyopathy. Curr Treat Options Cardiovasc Med (2004) 0.82
Applications of cardiac magnetic resonance in electrophysiology. Circ Arrhythm Electrophysiol (2009) 0.82
Differentiation of infiltrative cardiomyopathy from hypertrophic cardiomyopathy using high-sensitivity cardiac troponin T: a case-control study. BMC Cardiovasc Disord (2015) 0.82
A TASH experience: post-infarction myocardial oedema necessitating the support of ECMO and occurrence of significant mitral regurgitation. Clin Res Cardiol (2011) 0.82
Genetic considerations in hypertrophic cardiomyopathy. Prog Cardiovasc Dis (2012) 0.81
Peak systolic longitudinal strain of the lateral left ventricular wall improves after septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: a follow-up study using speckle tracking echocardiography. Int J Cardiovasc Imaging (2010) 0.81
Timing of high-intensity pulses for myocardial cavitation-enabled therapy. J Ther Ultrasound (2014) 0.81
Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy. Circ Cardiovasc Genet (2013) 0.81
Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: a comparison between cardiac MRI, invasive measurements and echocardiography. Clin Res Cardiol (2010) 0.81
A systematic approach to echocardiography in hypertrophic cardiomyopathy: a guideline protocol from the British Society of Echocardiography. Echo Res Pract (2015) 0.81
Evaluation of left ventricular function, rotation, twist and untwist in patients with hypertrophic cardiomyopathy. Exp Clin Cardiol (2013) 0.80
Structural and kinetic effects of hypertrophic cardiomyopathy related mutations R146G/Q and R163W on the regulatory switching activity of rat cardiac troponin I. Arch Biochem Biophys (2012) 0.80
Alterations in cell adhesion proteins and cardiomyopathy. World J Cardiol (2014) 0.80
Impact of Mendelian inheritance in cardiovascular disease. Ann N Y Acad Sci (2010) 0.80
Rest perfusion abnormalities in hypertrophic cardiomyopathy: correlation with myocardial fibrosis and risk factors for sudden cardiac death. Clin Radiol (2015) 0.80
A delta-sarcoglycan gene polymorphism as a risk factor for hypertrophic cardiomyopathy. Genet Test Mol Biomarkers (2012) 0.80
Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment. CMAJ (2012) 0.80
Comparison of three current sets of electrocardiographic interpretation criteria for use in screening athletes. Heart (2014) 0.79
Cardiovascular magnetic resonance: applications in daily practice. Cardiol Rev (2011) 0.79
Heart rate recovery in patients with hypertrophic cardiomyopathy. Am J Cardiol (2013) 0.79
Effect of alcohol septal ablation in patients with hypertrophic cardiomyopathy on left-ventricular mechanical dyssynchrony as assessed by phase analysis of gated SPECT myocardial perfusion imaging. Int J Cardiovasc Imaging (2011) 0.79
A clinical approach to inherited hypertrophy: the use of family history in diagnosis, risk assessment, and management. Circ Cardiovasc Genet (2013) 0.79
Hypertrophic cardiomyopathy and ultra-endurance running - two incompatible entities? J Cardiovasc Magn Reson (2011) 0.79
Circulating matrix metalloproteinases in adolescents with hypertrophic cardiomyopathy and ventricular arrhythmia. Circ Heart Fail (2012) 0.79
Prevalence of aortic dilation in hypertrophic cardiomyopathy. Am J Cardiovasc Dis (2013) 0.79
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Curr Cardiol Rev (2008) 0.78
Cardiogenic shock due to dynamic left ventricular outflow tract obstruction in acute myocardial infarction. Clin Res Cardiol (2011) 0.78
Epidemiology and cost of heart failure in children. Cardiol Young (2015) 0.78
Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy. Heart (2007) 0.78
Phenotype and prognostic correlations of the converter region mutations affecting the β myosin heavy chain. Heart (2015) 0.78
Effects of lifestyle changes and high-dose β-blocker therapy on exercise capacity in children, adolescents, and young adults with hypertrophic cardiomyopathy. Cardiol Young (2014) 0.78
[The ICD as primary prevention. Rare indications]. Herzschrittmacherther Elektrophysiol (2010) 0.78
Myocardial triglyceride content in patients with left ventricular hypertrophy: comparison between hypertensive heart disease and hypertrophic cardiomyopathy. Heart Vessels (2016) 0.77
Acute and reversible cardiomyopathy provoked by stress in women from the United States. Circulation (2005) 6.85
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation (2010) 6.71
Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2007) 6.34
Truncations of titin causing dilated cardiomyopathy. N Engl J Med (2012) 6.07
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J (2014) 5.21
Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. Science (2007) 5.19
Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med (2003) 5.17
De novo mutations in histone-modifying genes in congenital heart disease. Nature (2013) 5.15
A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med (2009) 4.54
Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol (2008) 4.51
Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol (2003) 4.36
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J (2010) 4.13
De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. Nat Genet (2009) 3.86
Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation (2006) 3.82
Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation (2008) 3.77
A public resource facilitating clinical use of genomes. Proc Natl Acad Sci U S A (2012) 3.72
Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science (2003) 3.71
Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med (2005) 3.71
Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol (2002) 3.71
Diagnosis of left-ventricular non-compaction in patients with left-ventricular systolic dysfunction: time for a reappraisal of diagnostic criteria? Eur Heart J (2007) 3.65
Remodeling of myocyte gap junctions in arrhythmogenic right ventricular cardiomyopathy due to a deletion in plakoglobin (Naxos disease). Heart Rhythm (2004) 3.54
Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline. J Card Fail (2009) 3.54
Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol (2010) 3.50
Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med (2010) 3.42
Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol (2008) 3.42
Prevalence and clinical significance of left atrial remodeling in competitive athletes. J Am Coll Cardiol (2005) 3.42
Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med (2016) 3.40
The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet (2005) 3.36
Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest (2002) 3.33
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA (2007) 3.32
Outcomes in athletes with marked ECG repolarization abnormalities. N Engl J Med (2008) 3.30
Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J (2006) 3.22
Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol (2010) 3.21
Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation (2002) 3.20
Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation (2005) 3.11
Natural history and familial characteristics of isolated left ventricular non-compaction. Eur Heart J (2004) 3.02
Ebstein's anomaly. Circulation (2007) 2.90
Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol (2008) 2.82
Genetic causes of human heart failure. J Clin Invest (2005) 2.79
Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation (2012) 2.78
Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging (2012) 2.76
Filter-based hybridization capture of subgenomes enables resequencing and copy-number detection. Nat Methods (2009) 2.71
Cardiac myosin-binding protein-C phosphorylation and cardiac function. Circ Res (2005) 2.67
Comparison of circadian rhythm patterns in Tako-tsubo cardiomyopathy versus ST-segment elevation myocardial infarction. Am J Cardiol (2012) 2.66
Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J Clin Invest (2010) 2.64
Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation (2007) 2.56
Hypertrophic cardiomyopathy. Anesthesiology (2006) 2.54
Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy. Circ Cardiovasc Imaging (2011) 2.54
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2011) 2.53
Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. Am J Cardiol (2003) 2.50
Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. J Am Coll Cardiol (2004) 2.49
Cardiac myosin binding protein C phosphorylation is cardioprotective. Proc Natl Acad Sci U S A (2006) 2.46
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol (2005) 2.43
EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. J Am Soc Echocardiogr (2012) 2.41
Hypertrophic cardiomyopathy. Lancet (2004) 2.41
Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol (2004) 2.40
Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis. Nat Genet (2012) 2.39
Evidence for efficacy of the Italian national pre-participation screening programme for identification of hypertrophic cardiomyopathy in competitive athletes. Eur Heart J (2006) 2.38
Recommendations for interpretation of 12-lead electrocardiogram in the athlete. Eur Heart J (2009) 2.37
Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation (2005) 2.35
Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation (2003) 2.28
AMP-activated protein kinase in the heart: role during health and disease. Circ Res (2007) 2.27
Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet (2002) 2.27
The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest (2002) 2.26
Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. Am J Hum Genet (2006) 2.26
Long-term clinical consequences of intense, uninterrupted endurance training in olympic athletes. J Am Coll Cardiol (2010) 2.24